Buzz Stocks: Alibaba Group Holding Ltd, Infinity Pharmaceuticals Inc., and Valeant Pharmaceuticals Intl Inc

Today's stocks to watch in the news include Alibaba Group Holding Ltd (NYSE:BABA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI), and Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

Jun 14, 2016 at 9:28 AM
facebook twitter linkedin

U.S. stocks are pointing to a lower start this morning, as anxiety swirls ahead of the Fed's two-day policy-deciding meeting. Among the equities in focus today are Chinese e-tailer Alibaba Group Holding Ltd (NYSE:BABA), as well as biotech stocks Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

  • BABA has added almost 2% in pre-market trading, after the company announced it expects transactions volume to nearly double by 2020 and for revenue to grow by 48% in fiscal year 2017. The stock has experienced whipsaw price action this year, with Monday's settlement at $75.45 leaving the shares 7.2% lower year-to-date. Regardless, analysts have remained upbeat, with 89% of the brokerage firms tracking Alibaba Group Holding Ltd calling it a "buy" or better, with no "sell" ratings on the books. 
  • Yesterday, INFI fell to a seven-year low of $4.38, before closing at $4.41 -- 60% lower year-over-year. More losses are in store for the stock today, as the shares have plummeted over 67% in electronic trading -- on pace to open at an all-time low -- after the company announced a restructuring plan that would cut one-fifth of its workforce. The news follows disappointing mid-stage trial results for Infinity Pharmaceuticals Inc.'s non-Hodgkin lymphoma treatment. J.P. Morgan Securities downgraded the stock to "neutral" as a result, and more bearish notes could come, since six analysts still call INFI a "buy" or better. 
  • VRX is edging higher this morning, ahead of the company's annual shareholders meeting, scheduled for 9 a.m. ET. As new CEO Joseph Papa prepares to assure investors the company is on the right track after a 90% collapse in the stock over the past 12 months, reports are surfacing that Valeant Pharmaceuticals Intl Inc is working to sell its dermatology businesses. At $23.78, VRX is sitting just above its five-year low of $22.52 from last week, but short-term options traders remain more call-skewed than normal. Specifically, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.88 ranks just 4 percentage points from a 12-month low
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!